



Astec LifeSciences Ltd.

Dated: 14th February, 2013

To,
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra, Mumbai-400051

Ref: "ASTEC"

Sub: Outcome of Board Meeting

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on 14th February 2013 has:

- 1) Approved the Consolidated and Standalone Unaudited Financial Results for the quarter ended 31.12.2012. (enclosed herewith)
- 2) Approved the Limited Review Report on Unaudited Financial Results for the quarter ended 31.12.2012. (enclosed herewith)

Please take the same on your records.

Thanking you,

Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED

Vikas R. Chomal
Company Secretary & Compliance Officer



Encl: as above



ISO 9001
International Standards
Certifications
ISO 9001:2008



ISO 14001
International Standards
Certifications
ISO 14001:2004



OHSAS 18001
International Standards
Certifications
OHSAS 18001:2007

Head Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone: +91-22- 2261 8212/ 2261 8504
Fax : +91-22- 2261 8289
E-mail : ah@astecsls.com
Website : www.astecsls.com

STANDARD ONE

CONSOLIDATED

Sr. No	Particulars	Rs. in Lacs (Except for per share data)											
		Quarter Ended			Year Ended			Quarter Ended			Year Ended		
		31/12/2012 (Unaudited)	30/09/2012 (Unaudited)	31/12/2011 (Unaudited)	31/12/2012 (Unaudited)	31/12/2011 (Unaudited)	31/03/2012 (Audited)	31/12/2012 (Unaudited)	30/09/2012 (Unaudited)	31/12/2011 (Unaudited)	31/12/2012 (Unaudited)	31/12/2011 (Unaudited)	31/03/2012 (Audited)
1	Income from Operations												
	a) Net Sales / Income from operations (Net of Excise Duty)	3,925.51	3,853.01	2,822.61	10,831.78	8,469.96	11,084.06	4,055.78	4,411.65	2,922.13	11,726.91	8,693.45	11,284.48
	b) Other Operating Income	8.39	11.76	40.30	37.57	112.60	74.01	9.26	15.46	25.34	44.31	86.34	32.58
	Total Income from Operations (net)	3,933.91	3,865.77	2,862.91	10,869.35	8,582.56	11,158.07	4,065.05	4,427.11	2,947.47	11,771.23	8,779.79	11,317.06
2	Expenses												
	a) Cost of materials consumed	2,327.27	2,300.70	2,696.27	6,597.56	6,394.96	8,472.21	2,480.64	3,345.62	2,956.88	7,366.27	6,904.08	8,923.94
	b) Purchases of stock in trade			495.21	696.99	696.99	696.99				495.21	696.99	696.99
	c) Changes in inventories of finished goods and work in progress	136.55	(235.32)	(657.20)	(48.24)	(681.72)	(832.86)	98.69	(258.52)	(855.61)	(214.77)	(1,194.66)	(1,174.91)
	d) Employee benefits expenses	232.28	190.09	165.38	582.25	380.21	471.79	257.65	232.57	193.76	671.11	557.53	557.53
	e) Depreciation and amortisation expenses	314.99	308.53	214.47	887.15	623.30	847.54	326.23	303.78	215.72	870.88	627.04	883.79
	f) Other expenditure	436.30	436.30	136.40	1,225.06	317.49	441.73	539.54	476.19	169.59	1,366.60	479.97	540.41
	Total Expenses	3,480.28	3,602.30	2,555.32	9,708.98	7,731.21	10,116.39	3,702.75	4,105.64	2,680.34	10,555.31	7,940.76	10,407.74
3	Profit / (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)	353.63	263.46	307.59	1,160.37	851.35	1,041.67	362.30	321.46	267.13	1,215.92	839.03	909.31
4	Other Income	28.03	58.70		133.66		27.88	28.03	43.44		118.40		28.73
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	381.65	322.16	307.59	1,294.03	851.35	1,069.55	390.32	364.90	267.13	1,334.31	839.03	938.04
6	Finance Costs	171.58	183.04	162.81	544.21	399.14	534.29	218.87	193.95	175.41	621.87	418.37	555.92
6A	Foreign Exchange Fluctuation (Profit) / Loss	142.40	(231.28)	73.34	172.05	115.06	176.83	176.83	(231.28)	73.34	172.05	115.06	176.83
7	Profit after finance costs but before Exceptional Items (5-6A)	67.68	370.40	71.44	577.66	337.15	358.43	37.06	402.23	18.38	540.40	305.60	195.29
8	Exceptional Items (Includes adjustment relating to previous year)	0.08	18.74	2.01	21.69	3.47	14.11	0.08	18.74	2.01	21.69	3.46	14.11
9	Profit / (Loss) from ordinary activities before tax (7-8)	67.60	351.66	69.43	555.97	333.68	344.32	36.98	383.49	16.37	518.21	302.14	181.18
10	Tax Expense	34.21	87.99	13.59	183.40	66.74	102.52	34.21	103.19	13.79	186.66	68.42	53.79
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	33.39	263.67	55.84	372.57	266.93	241.80	2.77	280.30	2.58	332.05	233.72	127.39
12	Extra ordinary Items												
13	Net Profit / (Loss) for the period (11 - 12)	33.39	263.67	55.84	372.57	266.93	241.80	2.77	280.30	2.58	332.05	233.72	127.39
14	Share of Profit / (Loss) of associates												
15	Minority Interest												
16	Net Profit / (Loss) after taxes, minority interest and share of profit	33.39	263.67	55.84	372.57	266.93	241.80	0.15	0.15	0.15	0.29	0.30	(9.17)
17	Paid-up equity share capital (Face Value Rs.10/-)	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	2.62	280.17	2.43	331.75	233.42	136.56
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year							1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91
19	Earnings per share - Basic & Diluted	0.20	1.56	0.33	2.20	1.58	1.43	0.02	1.65	0.16	1.96	1.38	0.81
PART II													
A PARTICULARS OF SHAREHOLDING													
1	Public shareholding												
	- No of shares	74,97,150	74,97,150	75,00,150	74,97,150	75,00,150	74,97,150	74,97,150	74,97,150	75,00,150	74,97,150	75,00,150	74,97,150
	- Percentage of shareholding	44.29%	44.29%	44.30%	44.29%	44.30%	44.29%	44.29%	44.29%	44.30%	44.29%	44.30%	44.29%
2	Promoters and promoter Group shareholding												
	a) Pledged / Encumbered												
	- No of shares	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total shareholding of promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered												
	- No of shares	94,31,980	94,31,980	94,28,980	94,31,980	94,28,980	94,31,980	94,31,980	94,31,980	94,28,980	94,31,980	94,28,980	94,31,980
	- Percentage of shares (as a % of the total shareholding of promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	55.71%	55.71%	55.70%	55.71%	55.70%	55.71%	55.71%	55.71%	55.70%	55.71%	55.70%	55.71%
B INVESTOR COMPLAINTS													
	Pending at the beginning of the quarter												
	Received during the quarter												
	Disposed of during the quarter												
	Remaining unresolved at the end of the quarter												
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on February 14, 2013.												
2	The company has only one reportable segment i.e. Agrochemicals & Pharma intermediates.												
3													
4	Above Financial Results includes financials results of M/s Behram Chemicals Pvt. Ltd. (65.63% subsidiary) Astec Europe SpA (50.10% subsidiary) and Astec CropCare Pvt Ltd (100% Subsidiary of Astec).												
5	Figures of the previous period have been regrouped/rearranged, wherever necessary, to conform with the financial information of the company's given below:-												
Particulars													
	Net Sales / Income from operations (Net of Excise Duty)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Other Operating Income	3,925.51	2,822.61	10,831.78	8,469.96	11,084.06	74.01	9.26	15.46	25.34	44.31	86.34	32.58
	Profit / (Loss) from ordinary activities before tax	8.39	40.30	37.57	112.60	74.01	74.01	9.26	15.46	25.34	44.31	86.34	32.58
	Net Profit / (Loss) from ordinary activities after tax	67.60	69.43	555.97	333.68	344.32	344.32	36.98	383.49	16.37	518.21	302.14	181.18
	Earnings per share - Basic & Diluted	0.20	0.33	2.20	1.58	1.43	1.43	0.02	1.65	0.16	1.96	1.38	0.81

For Astec LifeSciences Limited
(Ashok V Hiremath)
Chairman & Managing Director
Mumbai, February 14, 2013





P.M. Kathariya & Co.

Chartered Accountants

Room No. 6, Kermani Bldg., 4th Floor, 27
Sir P. M. Road, Fort, Mumbai - 400 001.

Tel. : 66315862, Telefax : 22856615, R. : 28728803

Mobile : 9821034665

Email : pmkathariya@rediffmail.com

pmkathariya@gmail.com

LIMITED REVIEW REPORT

The Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statements of Un-audited Financial Results of Astec LifeSciences Limited (the 'Company') for the quarter ended December 31, 2012, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited or reviewed by us. These Statements are the responsibility of the Company's management and have been approved by the Board of Directors. Our responsibility is to issue a report on the Statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements of Un-audited Financial Results, prepared in accordance with applicable Accounting Standards notified pursuant to Companies (Accounting Standards) Rules, 2006 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed or that it contains any material misstatement.

Place: Mumbai

Date: 13 February 2013



For P. M. KATHARIYA & CO.
Chartered Accountants

anai/917
C.A.-P.M. KATHARIYA
(Proprietor)
M. No. 31315